Eighteen nucleic acid therapeutics have been approved for treatment of various diseases in
the last 25 years. Their modes of action include antisense oligonucleotides (ASOs), splice …

MicroRNAs (miRNAs) are very powerful genetic regulators, as evidenced by the fact that a
single miRNA can direct entire cellular pathways via interacting with a broad spectrum of …

The discovery of the link between microRNAs (miRNAs) and a myriad of human diseases,
particularly various cancer types, has generated significant interest in exploring their …

Advances in hydrogel technology have unlocked unique and valuable capabilities that are
being applied to a diverse set of translational applications. Hydrogels perform functions …

Oligonucleotides can be used to modulate gene expression via a range of processes
including RNAi, target degradation by RNase H-mediated cleavage, splicing modulation …

Nucleic acid‐based therapeutics that regulate gene expression have been developed
towards clinical use at a steady pace for several decades, but in recent years the field has …

While Nature harnesses RNA and DNA to store, read and write genetic information, the
inherent programmability, synthetic accessibility and wide functionality of these nucleic acids …

Emerging therapeutics that utilize RNA interference (RNAi) have the potential to treat broad
classes of diseases due to their ability to reversibly silence target genes. In August 2018, the …

Soon after they were first described in 1990, aptamers were largely recognized as a new
class of biological ligands that can rival antibodies in various analytical, diagnostic, and …

After nearly 40 years of development, oligonucleotide therapeutics are nearing meaningful
clinical productivity. One of the key advantages of oligonucleotide drugs is that their delivery …